Prothrombotic states that predispose to stroke
Authors:
- 1 November 2002
- journal article
- research article
- Published by Springer Nature in Current Treatment Options in Neurology
- Vol. 4 (6) , 417-425
Abstract
Hereditary prothrombotic states of clinical importance include factor V Leiden, the prothrombin 20210A mutation, deficiencies of protein C, protein S, or antithrombin, sickle cell disease, and hyperhomocysteinemia. Major acquired prothrombotic states include cancer, myeloproliferative disorders, the antiphospholipid syndrome, and heparin-induced thrombocytopenia. Because most of the hereditary prothrombic states are not established risk factors for arterial thrombosis, routine laboratory testing in most patients with ischemic stroke should be limited to complete blood count, lupus anticoagulant, anticardiolipin antibodies, and plasma total homocysteine. Additional testing for factor V Leiden, prothrombin 20210A, antithrombin, protein C, and protein S may be indicated for patients under the age of 50 or those with paradoxical cerebral embolism. The treatment of acute ischemic stroke in patients with prothrombotic states is similar to that in patients without an identifiable prothrombotic condition, and may include antiplatelet agents, anticoagulants, or thrombolytic therapy in patients who otherwise meet eligibility criteria. The potential benefit of chronic anticoagulation therapy for the primary or secondary prevention of stroke in patients with prothrombotic states has not been addressed in controlled clinical trials. Specific therapeutic approaches for the prevention of stroke are established for patients with sickle cell disease, myeloproliferative disorders, and heparininduced thrombocytopenia, and are under investigation for hyperhomocysteinemia and the antiphospholipid syndrome.Keywords
This publication has 47 references indexed in Scilit:
- The contribution of prothrombotic states to cancer-related strokeSeminars in Cerebrovascular Diseases and Stroke, 2002
- β 2 -Glycoprotein 1–Dependent Anticardiolipin Antibodies and Risk of Ischemic Stroke and Myocardial InfarctionStroke, 2001
- Homocysteine and Its Disulfide DerivativesArteriosclerosis, Thrombosis, and Vascular Biology, 2000
- Management of Patients with Hereditary Hypercoagulable DisordersAnnual Review of Medicine, 2000
- International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International workshopArthritis & Rheumatism, 1999
- HOMOCYSTEINE METABOLISMAnnual Review of Nutrition, 1999
- Inherited Prothrombotic Conditions and Premature Ischemic StrokeArteriosclerosis, Thrombosis, and Vascular Biology, 1999
- The Effect of Folic Acid Fortification on Plasma Folate and Total Homocysteine ConcentrationsNew England Journal of Medicine, 1999
- Homocysteine and Cardiovascular DiseaseAnnual Review of Medicine, 1998
- VASCULAR OCCLUSIVE EPISODES AND VENOUS HÆMATOCRIT IN PRIMARY PROLIFERATIVE POLYCYTHÆMLXThe Lancet, 1978